MedTrace Logo

Effects of CS-8080 in Healthy Volunteers

NCT00613431 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2018-12-21

No results posted yet for this study

Summary

The main purposes of this study are to assess the safety and measure the pharmacokinetics of CS-8080 in healthy volunteers.

Conditions

  • Healthy

Interventions

DRUG

CS8080

CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.

DRUG

Placebo

Some subjects will receive matching placebo instead of CS-8080.

Sponsors & Collaborators

Principal Investigators

  • Robert Noveck, MD · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613431 on ClinicalTrials.gov